Jacobs Levy Equity Management
BIOA

Jacobs Levy Equity Management’s BioAge Labs BIOA Stock Holding History

Jacobs Levy Equity Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.35M Buy
420,123
+85,997
+26% +$1.66M 0.03% 351
2025
Q4 		$4.42M Buy
334,126
+121,038
+57% +$1.07M 0.02% 432
2025
Q3 		$1.25M Sell
213,088
-60,364
-22% -$283K 0.01% 672
2025
Q2 		$1.13M Buy
+273,452
New +$1.1M ﹤0.01% 735

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Jacobs Levy Equity Management's BIOA Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its BioAge Labs (BIOA) stake by 26% in Q1 2026, buying an estimated $1.66M and bringing the position to 420,123 shares worth $7.35M. The position accounts for 0.03% of the portfolio, ranked #351.

Jacobs Levy Equity Management first reported a position in BIOA in Q2 2025 and has held it in 4 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Jacobs Levy Equity Management held 420,123 shares of BioAge Labs worth $7.35M as of Q1 2026.
  • Jacobs Levy Equity Management bought 85,997 BioAge Labs shares in Q1 2026, an estimated $1.66M.
  • BioAge Labs made up 0.03% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #351 holding.
  • Jacobs Levy Equity Management first reported a position in BioAge Labs in Q2 2025 and has held it in 4 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.